Skip to Content

VitaSpring Biomedical Co Ltd Ordinary Shares VSBC

Morningstar Rating
$15.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

VSBC is trading at a 647% premium.
Price
$16.05
Fair Value
$52.54
Uncertainty
Extreme
1-Star Price
$91.26
5-Star Price
$2.27
Economic Moat
Vffcdx
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VSBC is a good fit for your portfolio.

Trading Information

Previous Close Price
$15.00
Day Range
$15.0015.00
52-Week Range
$11.0116.00
Bid/Ask
$8.00 / $18.15
Market Cap
$3.10 Bil
Volume/Avg
943 / 943

Key Statistics

Price/Earnings (Normalized)
3,629.76
Price/Sales
664.53
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

VitaSpring Biomedical Co Ltd is a start-up business company. The company's objective is to develop new drugs in cell medicine. The company also plans to produce X.MSC cytopharmaceuticals.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees

Comparables

Valuation

Metric
VSBC
PNT
CRNX
Price/Earnings (Normalized)
3,629.7611.36
Price/Book Value
1,908.623.124.81
Price/Sales
664.535.501,700.95
Price/Cash Flow
2,904.3413.90
Price/Earnings
VSBC
PNT
CRNX

Financial Strength

Metric
VSBC
PNT
CRNX
Quick Ratio
4.329.0117.59
Current Ratio
4.339.1417.72
Interest Coverage
Quick Ratio
VSBC
PNT
CRNX

Profitability

Metric
VSBC
PNT
CRNX
Return on Assets (Normalized)
42.38%20.67%−33.04%
Return on Equity (Normalized)
65.38%23.56%−37.88%
Return on Invested Capital (Normalized)
55.23%23.38%−39.10%
Return on Assets
VSBC
PNT
CRNX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
QqwkxwldmhXcg$591.2 Bil
Vertex Pharmaceuticals Inc
VRTX
VgjccmmjKvqhydp$128.0 Bil
Regeneron Pharmaceuticals Inc
REGN
DtztrxfjHthjlc$117.9 Bil
Moderna Inc
MRNA
PjxmrygbFsh$46.9 Bil
Alnylam Pharmaceuticals Inc
ALNY
PwsgtpdKkdgrbj$29.8 Bil
argenx SE ADR
ARGX
RdmbdcyQcrfp$27.9 Bil
BioNTech SE ADR
BNTX
NrckgqzxGhvw$20.7 Bil
Biomarin Pharmaceutical Inc
BMRN
YxpczskkTzppzhx$16.2 Bil
United Therapeutics Corp
UTHR
XswsqzfyRxyd$14.8 Bil
Royalty Pharma PLC Class A
RPRX
WybkmwjpprQzxzvbp$12.9 Bil

Sponsor Center